Johnson & Johnson
Statements
Segments
US companies must disclose in their mandatory reports how revenue breaks down across business segments, regions and product lines. We read that breakdown for you straight from the annual and quarterly reports (10-K and 10-Q) of Johnson & Johnson (JNJ). It shows which part of the business is growing — and which one is holding it back.
Revenue by business segment
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Innovative Medicine | – | $51.68B 65.6% | $52.56B 65.7% · +1.7% | $54.76B 64.3% · +4.2% | $56.96B 64.1% · +4.0% | $60.40B 64.1% · +6.0% |
| Medical Devices | $22.96B 27.8% | $27.06B 34.4% · +17.9% | $27.43B 34.3% · +1.4% | $30.40B 35.7% · +10.8% | $31.86B 35.9% · +4.8% | $33.79B 35.9% · +6.1% |
| Consumer Health | $14.45B 17.5% | – | – | – | – | – |
| Pharmaceutical | $45.18B 54.7% | – | – | – | – | – |
Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.
Segment and region names are the ones the company itself uses and are shown as reported. Change and share refer to revenue.
Data as of: August 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Segment figures: SEC EDGAR (10-K/10-Q reports)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.